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OBJECTIVE—To document the properties of the voltage-gated
ion channels in human pancreatic -cells and their role in
glucagon release.
RESEARCH DESIGN AND METHODS—Glucagon release
was measured from intact islets. [Ca
2]i was recorded in cells
showing spontaneous activity at 1 mmol/l glucose. Membrane
currents and potential were measured by whole-cell patch-
clamping in isolated -cells identiﬁed by immunocytochemistry.
RESULTS—Glucose inhibited glucagon secretion from human
islets; maximal inhibition was observed at 6 mmol/l glucose.
Glucagon secretion at 1 mmol/l glucose was inhibited by insulin
but not by ZnCl2. Glucose remained inhibitory in the presence of
ZnCl2 and after blockade of type-2 somatostatin receptors.
Human -cells are electrically active at 1 mmol/l glucose. Inhibi-
tion of KATP-channels with tolbutamide depolarized -cells by 10
mV and reduced the action potential amplitude. Human -cells
contain heteropodatoxin-sensitive A-type K
-channels, stroma-
toxin-sensitive delayed rectifying K
-channels, tetrodotoxin-
sensitive Na
-currents, and low-threshold T-type, isradipine-
sensitive L-type, and -agatoxin-sensitive P/Q-type Ca
2-channels.
Glucagon secretion at 1 mmol/l glucose was inhibited by 40–70%
by tetrodotoxin, heteropodatoxin-2, stromatoxin, -agatoxin,
and isradipine. The [Ca
2]i oscillations depend principally on
Ca
2-inﬂux via L-type Ca
2-channels. Capacitance measure-
ments revealed a rapid (50 ms) component of exocytosis.
Exocytosis was negligible at voltages below 20 mV and peaked
at 0 mV. Blocking P/Q-type Ca
2-currents abolished depolariza-
tion-evoked exocytosis.
CONCLUSIONS—Human -cells are electrically excitable, and
blockade of any ion channel involved in action potential depo-
larization or repolarization results in inhibition of glucagon
secretion. We propose that voltage-dependent inactivation of
these channels underlies the inhibition of glucagon secretion by
tolbutamide and glucose. Diabetes 59:2198–2208, 2010
G
lucagon is the principal hyperglycemic hor-
mone (1,2). It is secreted from the pancreatic
-cells in response to a fall in plasma glucose
levels, -adrenergic stimulation, lipids, and
amino acids (3–5). Glucagon secretion from -cells is
regulated by paracrine (3), neuronal (6), and intrinsic
mechanisms (7). Diabetes involves both impaired insulin
and glucagon secretion (8). Thus, hyperglucagonemia is
thought to contribute to elevated blood glucose levels, and
the impaired glucagon response to hypoglycemia repre-
sents a limiting factor for insulin treatment in both type 1
and type 2 diabetes (9,10).
Ion channels and electrical activity play a key role in the
regulation of glucagon secretion. The properties of rodent
-cells have been characterized in some detail (5,11–13).
Rodent -cells are electrically excitable and electrically
active in the absence of glucose. Action potential ﬁring
depends on the opening of voltage-activated L- and N-type
Ca
2-channels, tetrodotoxin (TTX)-sensitive Na
-chan-
nels, and A-type K
-channels (14).
The -cells make up 35% of the cell population in
human islets (15,16). Here, we have characterized the
electrophysiological properties of isolated human -cells
and correlated our ﬁndings to changes in glucagon secre-
tion from intact human islets. Our data indicate that
glucagon secretion depends on a complex interplay among
a number of depolarizing and repolarizing membrane
currents.
RESEARCH DESIGN AND METHODS
Islet isolation. Human pancreases were obtained with ethical approval and
clinical consent from nondiabetic donors. Islets were isolated in the Diabetes
Research & Wellness Foundation Human Islet Isolation Facility by collage-
nase digestion (Serva, Heidelberg, Germany), using modiﬁed versions of
published procedures (17,18).
Glucagon secretion assay. Islets were cultured overnight in CMRL me-
dium containing 5.5 mmol/l glucose and 2 mmol/l L-glutamine. Batches of
10–20 size-matched islets (in triplicates) were preincubated in Krebs-
Ringer buffer (KRB) containing 2 mg/ml BSA and 1 mmol/l glucose for 1 h
at 37°C, followed by a 1-h test incubation in KRB supplemented with
glucose and ion channel blockers as indicated. The glucagon content of the
supernatant was determined by radioimmunoassay (Millipore U.K. Ltd.,
Livingston, U.K.). Insulin and somatostatin were determined as described
previously (19,20).
Electrophysiology. Freshly isolated islets were dispersed into single cells by
trypsin digestion and plated onto plastic Petri dishes. The cells were cultured
in RPMI medium containing 10 mmol/l glucose prior to the experiments.
Patch-clamp experiments were performed by whole-cell measurements at
32°C as previously described (19).
The extracellular solution for membrane potential measurements con-
tained (in mM) 140 NaCl, 3.6 KCl, 0.5 MgSO4, 1.5 CaCl2, 10 HEPES, 0.5
NaH2PO4, 5 NaHCO3 (pH adjusted to 7.4 with NaOH), and glucose as
indicated. The extracellular solution for K
-current measurements con-
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glucose (pH 7.4, with NaOH). For all other experiments, 20 mmol/l TEACl
was added and NaCl was reduced correspondingly. Na
-o rC a
2-currents
were recorded in the presence of 1 mmol/l CoCl2 or 0.1 g/ml TTX,
respectively. The intracellular solution for recording voltage-gated K
-
currents was composed of (mM) 120 KCl, 1 MgCl2, 10 EGTA, 1 CaCl2,1 0
HEPES, and 3 MgATP (pH 7.2, with KOH). To measure voltage-gated Na
-
or Ca
2-currents, KCl was replaced equimolarly by CsCl. In capacitance
measurements, the pipette solution was composed of (mM) 125 Cs-
glutamate, 10 CsCl, 10 NaCl, 1 MgCl2, 5 HEPES, 0.05 EGTA, 3 MgATP, and
0.1 cAMP (pH 7.15 with CsOH).
Membrane potential recordings were made using the perforated-patch
whole-cell conﬁguration. The intracellular solution contained (mM) 76 K2SO4,
10 KCl, 10 NaCl, 1 MgCl2, 5 HEPES (pH 7.35 with KOH), and 0.24 mg/ml
amphotericin B (21).
Immunocytochemistry. Immunocytochemical identiﬁcation of patch-
clamped cells was performed as described previously (20,22).
[Ca
2]i measurements. Intact islets were loaded with the Ca
2-indicator
ﬂuo-4 AM (2.5 mol/l; Invitrogen, Carlsbad, CA) in CMRL medium for 1–8 h at
room temperature. The islets were immobilized in the recording chamber
using a wide-bore holding pipette and continuously perifused with KRB
containing 1 mmol/l glucose. The bath temperature was kept at 37°C. Laser
scanning confocal microscopy was performed using an LSM 510 META laser
scanning module (Zeiss) mounted on an Axioskop 2FS microscope. Images
were acquired at 2.5-s intervals and analyzed using Zeiss LSM 510 software.
Increases in [Ca
2]i are displayed as upward deﬂections.
Data analysis. All data are expressed as means 	 SEM. Glucagon secretion
data have (except for Fig. 1) been normalized to secretion measured at 1
mmol/l glucose in the absence of blockers. Statistical signiﬁcance was
evaluated using Student t test. All hormone secretion experiments were
repeated using islets from at least three donors.
RESULTS
Effects of glucose on pancreatic hormone release in
human islets. Glucagon secretion was measured from
intact human islets exposed to 1, 6, and 20 mmol/l glucose.
Increasing the glucose concentration inhibited glucagon
secretion; maximal inhibition (62%) was observed at 6
mmol/l glucose (Fig. 1A). Increasing glucose from 6 to 20
mmol/l was associated with reduced inhibition, as previ-
ously observed in mouse islets (23). The effects of glucose
on glucagon secretion were compared with those on
insulin and somatostatin secretion. At 6 mmol/l glucose,
stimulation of insulin and somatostatin secretion was only
37 and 21%, respectively, of that produced by 20 mmol/l
glucose (Fig. 1B and C).
The somatostatin-receptor subtype 2 speciﬁc antagonist
CYN-154806 (0.1 mol/l) did not affect the ability of 6
mmol/l glucose to inhibit glucagon secretion (Fig. 1D). It
was ascertained that the CYN-154806 antagonized the
effects of somatostatin on -cell membrane potential
and [Ca
2]i (supplementary Fig. S1, available in an
online appendix at http://diabetes.diabetesjournals.org/
cgi/content/full/db09-1505/DC1).
When applied at 1 mmol/l glucose, insulin (100 nmol/l)
inhibited glucagon secretion by 74%, similar to the inhibi-
tion produced by 6 mmol/l glucose. Addition of insulin to
islets exposed to 6 mmol/l glucose stimulated glucagon
secretion (Fig. 1E). ZnCl2 (30 mol/l) increased glucagon
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FIG. 1. Glucose dependence of glucagon secretion and effect of paracrine modulators. A–C: Secretion of glucagon (A), insulin (B), and
somatostatin (C) measured at 1, 6, and 20 mmol/l glucose. Data are from 50 donors (glucagon) or 33 donors (insulin and somatostatin). *P < 0.05,
**P < 0.01, ***P < 0.001 versus the previous lower glucose concentration. Glucagon secretion was signiﬁcantly lower at 20 mmol/l compared with
1 mmol/l glucose (P < 0.05). D: Glucagon secretion measured at 1 and 6 mmol/l glucose under control conditions and in the presence of 100 nmol/l
of CYN-154806 (CYN). 100%  3.4  0.4 pg glucagon/islet/h. E:A si nD but in the absence and presence of 100 nmol/l insulin. 100%  4.9  0.9
pg glucagon/islet/h. F:A si nD but in the absence and presence of 30 mol/l ZnCl2. 100%  3.8  0.5 pg glucagon/islet/h. D–F:* P < 0.05, **P <
0.01, ***P < 0.001 versus 1 mmol/l glucose (control) or as indicated by brackets.
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affect the suppression of glucagon release by glucose (Fig.
1F). Neither insulin nor ZnCl2 affected the spontaneous
[Ca
2]i-oscillations observed at 1 mmol/l glucose (supple-
mentary Fig. S2, available in an online appendix).
Voltage-gated K
-currents. All electrophysiological re-
cordings were conducted in individual human -cells
subsequently identiﬁed by immunocytochemistry. The
-cells had a membrane capacitance of 3.3 	 0.1 pF (n 

197).
Voltage-gated membrane currents were recorded using
the standard whole-cell conﬁguration. Outward voltage-
activated K
-currents became detectable during mem-
brane depolarizations from 70 to 30 mV and above
(Fig. 2A and B). At 30 mV, the K
-current inactivated
completely within 20 ms, whereas a sustained compo-
nent was observed during depolarizations to 20 mV and
above (Fig. 2B). The peak amplitude recorded during
depolarizations to 0 mV averaged 349 	 61 pA (n 
 8). The
inactivation of the current could be described as the sum
of two exponentials with time constants (at 30 mV) of
18 	 2 and 567 	 147 ms (n 
 7). The sustained current
inactivated by 90% over 15 s (Fig. 2A, inset).
Figure 2C shows the I–V relationship recorded from
eight cells. In three of the eight cells, a prominent shoulder
on the I–V was seen at membrane potentials between 30
and 50 mV. Figure 2D shows the peak current, the
sustained current measured at the end of the 500 ms
depolarization, and the difference between the peak and
the sustained currents in one of these cells. The difference
current peaked at 30 mV. Similar current responses are
seen in human -cells (20) and reﬂect activation of large-
conductance Ca
2-activated K
-channels (BK-channels;
compare with ref [24]).
The broad-spectrum K
-channel blocker tetraethylam-
monium (TEA) (10 mmol/l) inhibited 74 	 2% (n 
 6; P 
0.01) of the peak current and 87 	 4% (n 
 6; P  0.01) of
the sustained current evoked by depolarizations to 30
mV (Fig. 3A). The TEA-resistant transient component was
completely blocked by 4-aminopyridine (5 mmol/l, n 
 4;
Fig. 2A). These pharmacological properties are those
expected for A-type K
-currents (A-current) (25). The
selective KV2.1/2.2 channel blocker stromatoxin (26) re-
duced the sustained current by 88 	 5% (P  0.01, n 
 4)
but decreased the peak current by only 33 	 15% (P 

0.05; Fig. 3B). During depolarizations to 0 mV, the TEA-
and stromatoxin-resistant A-current underwent rapid acti-
vation and inactivation. In seven different cells, the time
constants of activation (n) and inactivation (h) averaged
0.26 	 0.06 and 12 	 3 ms, respectively (n and h were
estimated assuming n
4h kinetics). n decreased with in-
creasing voltages (reﬂecting more rapid activation),
whereas no clear voltage dependence of h was observed
(not shown). The A-current was sensitive to the selective
KV4.x-antagonist heteropodatoxin-2 (27) (Fig. 3C; n 
 3).
Steady-state inactivation of voltage-gated K
-currents
was examined using two-pulse protocols in which condi-
tioning pulses to between 90 and 20 mV preceded an
activating test pulse (Figs. 3D and E). Both the A-type and
the sustained K
-current underwent voltage-dependent
inactivation that could be described by Boltzmann func-
tions (Fig. 3F). Half-maximal inactivation (Vh)o ft h e
A-current (studied in the presence of TEA) was observed
at 49 	 2 mV; the slope factor (nh) averaged 4.8 	 0.4
mV (n 
 7; Fig. 3D and F). The delayed-rectiﬁer current
(ignoring the initial 50 ms to avoid contamination by the
A-current) inactivated at more positive potentials with Vh
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FIG. 2. Analysis of voltage-gated K
-currents. A: Family of voltage-activated K
-currents (lower) evoked by depolarizing pulses from 70 mV to
membrane potentials between 40 and 80 mV. Inset shows inactivation of current during a 15-s depolarization from 70 to 20 mV. B:A si n
A but showing the initial part of the current responses during pulses to 40, 30, 20, and 10 mV on an expanded time base (sections
highlighted in gray in A). C: I–V relationship for voltage-gated K
-current (n  8). D: Example of a cell showing a clear shoulder on the I–V at
voltages between 30 and 50 mV. Data are shown for the peak current (squares), the sustained current measured at the end of the 500-ms pulse
(circles), and the difference (triangles).
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(n 
 5; Fig. 3E and F).
The recovery of A-current from inactivation was mea-
sured by application of two 50-ms test pulses to 30 mV
separated by a conditioning pulse to 70 mV of increasing
duration. The current recovered rapidly with a time con-
stant of 45 	 7m s( n 
 4; supplementary Fig. 3A and B,
available in an online appendix). This behavior is charac-
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FIG. 3. Pharmacological characterization of voltage-gated K
-currents. A: Current responses recorded during depolarizations to 20 mV under
control conditions, after addition of 10 mmol/l TEA (gray trace) and after addition of 5 mmol/l 4-aminopyridine in the continued presence of TEA
(n  4). B:A si nA but pulse went to zero and currents were recorded in the absence and presence of stromatoxin (100 nmol/l, n  4). C:A si n
A but pulse went to 10 mV and currents were recorded in the presence of 10 mmol/l TEA before and after application of heteropodatoxin-2 (0.5
mol/l). D: Steady-state inactivation of the A-current analyzed by a two-pulse protocol consisting of a 200-ms conditioning pulse to membrane
potentials between 90 and 20 mV followed by a 100-ms test pulse to 30 mV after an interval of 10 ms. Experiments were performed using
the perforated-patch technique in the presence of TEA. E: Steady-state inactivation of the delayed-rectifying K
-current was measured by
applying 15-s conditioning pulses to membrane potentials between 60 and 20 mV followed by a 500-ms test pulse to 20 mV (interval 10 ms).
F: Voltage dependence of inactivation of A-current (closed circles) and delayed-rectiﬁer current (open circles). The responses after conditioning
pulses to 90 and 60 mV, respectively, were taken as unity, and data are presented as a fraction of the maximal current displayed against the
voltage during the conditioning pulse. A Boltzmann function has been ﬁt to the data points (n  5–7). G: Glucagon secretion measured in the
absence (open bars) and presence (ﬁlled bars) of 0.5 mol/l heteropodatoxin-2 at 1 or 6 mmol/l glucose. *P < 0.01 versus 1 mmol/l glucose alone.
100%  6.5  0.8 pg/islet/h (n  12; 4 donors). H: Effects of 100 nmol/l stromatoxin on glucagon secretion at 1 or 20 mmol/l glucose. *P < 0.05
versus 1 mmol/l glucose. 100%  7.5  1.5 pg/islet/h (n  9; 3 donors).
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rectiﬁer K
-current recovered from inactivation (induced
by a 15-s depolarization to 20 mV) with a  of 2.9 	 0.7 s
(n 
 4, supplementary Fig. 3C).
Glucagon secretion at 1 mmol/l glucose was inhibited by
heteropodatoxin-2 (Fig. 3G) and stromatoxin (Fig. 3H).
The inhibitory effect of the K
-channel blockers was
comparable to that produced by 6 or 20 mmol/l glucose.
Glucose did not exert any additional inhibitory effect in the
presence of either blocker. Blockade of A-currents with
4-aminopyridine (5 mmol/l) inhibited glucagon secretion
as strongly as heteropodatoxin-2 (not shown).
Voltage-gated Na
-currents. Voltage-gated inward cur-
rents were studied using Cs
2-containing pipette solution
and TEA-containing bath solution to block K
-currents.
Figure 4A shows membrane currents elicited by 5-ms
depolarizations from 70 to 0 mV. Under control condi-
tions, the response consisted of an initial transient com-
ponent followed by a sustained current. The sustained
current was inhibited by the broad-spectrum Ca
2-channel
blocker Co
2 (1 mmol/l). In the presence of Co
2, a rapidly
activating and inactivating current was observed that was
inhibited by the Na
-channel blocker TTX.
The Na
-current became detectable during depolariza-
tions to 30 mV and above (Fig. 4B). The I–V relationship
exhibited a U-shaped voltage dependence with a maximal
amplitude of 38 	 3p Aa t0m V( n 
 5; Fig. 4C). Both the
activation and deactivation of the Na
-current became
faster with increasing voltages (not shown).
The Na
-current in human -cells undergoes voltage-
dependent inactivation (Fig. 4D). The steady-state inacti-
vation properties are summarized in Fig. 4E; Vh and nh
averaged 40 	 2 and 5 	 1m V( n 
 6), respectively.
The effect of the Na
-channel blocker TTX on glucagon
secretion from intact human islets is shown in Fig. 4F. The
inclusion of TTX in the extracellular medium reduced
glucagon secretion as strongly as 20 mmol/l glucose, and
glucose lacked further inhibitory action in the presence of
the blocker.
Voltage-gated Ca
2-currents. Voltage-gated Ca
2-cur-
rents (responsible for the sustained current component in
Fig. 4A) were examined in the presence of the Na
-
channel blocker TTX. Figure 5A shows a family of voltage-
clamp currents elicited by membrane depolarization from
70 mV to voltages between 60 and 0 mV. The voltage
dependence of the -cell Ca
2-current is shown in Fig. 5B.
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FIG. 4. Voltage-gated TTX-sensitive Na
-channels. Experiments were performed in the presence of TEA (10 mmol/l) in the extracellular solution
and after replacing K
 with Cs
 in the pipette solution. A: Currents recorded under control conditions, after addition of 1 mmol/l Co
2 and after
addition of TTX (0.1 g/ml) in the continued presence of Co
2. B: Voltage dependence of Na
-currents. The responses recorded in the presence
of Co
2 during depolarizations to 40, 30, 20, and 10 mV are shown. C: I–V relationship for Na
-currents (n  5). D: Inactivation of
Na
-current. A test pulse to 10 mV was preceded by 50-ms conditioning pulses to membrane potentials between 150 and 0 mV (60 to 30
shown). Currents were recorded in the presence of Co
2. E: Inactivation curve. The response after a conditioning pulse to 150 mV was taken
as unity (n  6). A Boltzmann function ﬁt to the mean data has been superimposed. F: Glucagon secretion measured in the absence (open bars)
and presence (ﬁlled bars) of TTX (0.1 g/ml) at 1 or 20 mmol/l glucose as indicated. 100%  12.2  3.8 pg/islet/h (n  15; 4 donors). *P < 0.05
versus 1 mmol/l glucose alone.
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and peaked at 0 mV, where the amplitude averaged 67 	
7p A( n 
 19).
The pharmacological properties of the Ca
2-current are
shown in Fig. 5C. The Ca
2-currents in human -cells are
sensitive to the L-type Ca
2-channel blocker isradipine
and the P/Q-type Ca
2-channel antagonist -agatoxin IVA.
The isradipine- and -agatoxin-sensitive currents ac-
counted for 21 	 4% (P  0.01; n 
 9) and 70 	 6% (P 
0.01; n 
 5) of the integrated Ca
2-current (QCa), respec-
tively. In addition, we observed a small current component
blocked by the N-type channel blocker -conotoxin GVIA
(11 	 3% reduction of QCa; P  0.01; n 
 13).
Voltage ramps between 80 and 50 mV were used to
determine the voltage dependence of the different Ca
2-
current components (Fig. 5D). Under control conditions,
inward currents became detectable above 50 mV and the
current amplitude then showed a triphasic dependence on
membrane potential: a shoulder between 40 and 20
mV, a secondary acceleration between 20 and 0 mV, and
a subsequent decline at more positive voltages (reﬂecting
the reduced electrochemical driving force). Also shown in
Fig. 5D are the responses recorded after addition of
isradipine alone and the combination of isradipine and
-agatoxin, respectively. Figure 5E shows the net isradip-
ine- (L-type; upper panel) and -agatoxin-sensitive (P/Q-
type; lower panel) Ca
2-currents. Whereas the activation
of the P/Q-type current was monophasic, that of the L-type
current was biphasic. The latter feature might reﬂect the
expression of two L-type Ca
2-channel isoforms in human
islets (1C and 1D; [20]). It is evident from Fig. 5D that a
small current component activating at negative voltages
(below 50 mV) is resistant to all these Ca
2-channel
blockers. This current reﬂects opening of low-threshold
T-type Ca
2-channels. Figure 5F shows current responses
elicited by ramps in the presence of isradipine alone and in
the combined presence of the T-type Ca
2-channel antag-
onist NNC 55-0396. The gray trace in Fig. 5F represents the
net NNC 55-0396-sensitive T-type Ca
2-current. The low-
threshold T-type current was seen in 10 of 14 cells and
gave rise to a rapidly inactivating current during depolar-
ization to 30 mV (Fig. 5G). The T-type current undergoes
voltage-dependent inactivation with values for Vh and nh
of 71 	 2 and 8 	 1 mV, respectively (n 
 6; Fig. 5G and
H). The T-type Ca
2-current was not observed during
depolarizations to 0 mV (Fig. 5C) because it is obscured by
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FIG. 5. Voltage-gated Ca
2-currents. Experiments were performed with TEA-containing extracellular and Cs
-containing pipette solution. A:
Family of voltage-gated Ca
2-currents recorded in the presence of TTX during 100-ms depolarizations to between 60 and 0 mV as indicated. B:
Current voltage relationship of whole-cell Ca
2-currents (n  14). C:C a
2-current recorded under control conditions and after addition of 10
mol/l isradipine and -conotoxin (100 nmol/l) and -agatoxin (200 nmol/l) in the continued presence of isradipine as indicated. D:C a
2-currents
elicited by voltage ramps (speed, 3 V/s) under control conditions and after addition of isradipine and -agatoxin in the continued presence of
isradipine (n  7, 7, 4 under control conditions, in the presence of isradipine, and after addition of -agatoxin, respectively). E: Isradipine- (top)
and -agatoxin-sensitive components (lower) from D. F:C a
2-currents elicited by voltage ramps in the presence of isradipine alone (10 mol/l)
and after addition of NNC 55-0396 (3 mol/l) in the continued presence of isradipine. The difference current (T-type; gray) is also shown. G:
Inactivation of the T-type Ca
2-current. A test pulse to 30 mV was preceded by 500-ms conditioning pulses to membrane potentials between 90
and 50 mV (in the presence of 10 mol/l isradipine). H: Voltage-dependent inactivation of T-type Ca
2-current. The current elicited after a
conditioning pulse to 100 mV was taken as unity. A Boltzmann ﬁt has been superimposed on the data points (n  6, experiments performed in
the presence of isradipine).
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 via
A-type K
-channels (not shown).
The L-type Ca
2-channel blocker isradipine inhibited
glucagon secretion from human islets at 1 mmol/l glucose
by 25% (Fig. 6A). Glucose retained an inhibitory action in
the presence of isradipine (P  0.05). Blocking the P/Q-
type Ca
2-channels exerted a stronger suppressor effect
and was as inhibitory as 20 mmol/l glucose (Fig. 6B).
Glucose did not diminish glucagon secretion when applied
in the presence of -agatoxin. The T-type Ca
2-channel
blocker 55-0396 paradoxically increased secretion at 1
mmol/l glucose by 190 	 30% (n 
 3; P  0.05) but did not
affect the inhibitory action of 20 mmol/l glucose (65 	 5%;
n 
 3; P  0.05; not shown). The stimulation of glucagon
secretion by the T-type Ca
2-channel blocker cannot be
attributed to inhibition of somatostatin or insulin secretion
(19,20) and may therefore reﬂect an unspeciﬁc action of
the compound.
Background membrane conductance, electrical activ-
ity, and [Ca
2]i. The background membrane conductance
of -cells was measured in the perforated-patch whole-cell
conﬁguration by applying 10 mV depolarizing pulses from
70 mV. The membrane conductance at 1 mmol/l glucose
averaged 0.12 	 0.01 nS (n 
 27). It was not reduced by
elevation of glucose to 6–10 mmol/l (0.12 	 0.04 nS; n 

13) or after addition of 100 mol/l tolbutamide (0.11 	 0.04
nS, n 
 13). However, diazoxide (100 mol/l) increased
the membrane conductance (from 0.14 	 0.05 to 0.32 	
0.12 nS; P 
 0.05, n 
 7).
Regenerative electrical activity was observed in 31 of 43
-cells analyzed (Fig. 7A). Of these, 76% were continuously
active, whereas the action potentials tended to be grouped
in bursts in the remaining 24% of the cells. Action poten-
tials were initiated from an average threshold potential of
42 	 1 mV and peaked at 2 	 1m V( n 
 26). The
membrane potential of -cells was unaffected by increas-
ing the glucose concentration (39 	 5 mV at 1 mmol/l
glucose and 37 	 4 mV at 6–10 mmol/l, n 
 15), but
tolbutamide (100–400 mol/l) depolarized the cells by
10 mV, from 42 	 3t o32 	 2m V( P  0.001, n 
 9).
This was associated with a reduction of action potential
peak voltage from 5 	 3t o12 	 2m V( P  0.05; Fig.
7B). Diazoxide (100 mol/l) hyperpolarized the -cell
membrane potential by 19 	 4m V( P  0.05, n 
 5; not
shown). For unknown reasons, regenerative electrical
activity subsided rapidly in most cells and was replaced by
small and irregular membrane potential oscillations. This
precluded a detailed analysis of the effects of different ion
channel blockers on -cell electrical activity.
Many cells in intact human islets exposed to 1 mmol/l
glucose exhibited spontaneous oscillations in cytosolic
Ca
2-concentration ([Ca
2]i). Of these cells, 71% re-
sponded with a large elevation of [Ca
2]i when exposed to
5 mol/l adrenaline (Fig. 7C). This feature is characteristic
of -cells in mouse islets (29). Experiments on isolated
human islet cells revealed that 77% of the cells that
responded to adrenaline with an elevation of [Ca
2]i were
-cells (as determined by immunocytochemistry). Addi-
tion of 200 nmol/l -agatoxin had a small inhibitory effect
on [Ca
2]i, whereas subsequent addition of 10 mol/l
isradipine was strongly inhibitory, an effect that could not
be antagonized by BayK8644 in islets that had been
exposed to -agatoxin (Fig. 7D). Application of isradipine
to islets that had not been exposed to -agatoxin also
reduced [Ca
2]i, but under these conditions, the effect was
partially antagonized by BayK8644 (Fig. 7E). The experi-
ments were concluded by depolarizing the cells with 70
mmol/l K
. The amplitude of the response to high [K
]o
was much larger when the cells had not been exposed to
-agatoxin (P  0.001).
Exocytosis in human -cells. High-resolution capaci-
tance measurements were applied to examine the exocy-
totic properties of individual -cells. The time course of
exocytosis was monitored by applying progressively
longer depolarizing pulses (20–500 ms) from 70 to 0 mV
(Fig. 8A). The amplitude of the responses was typically
fairly small and limited to 40 	 5f F( n 
 32) for a 500-ms
depolarization. However, pulses as short as 20 ms elicited
good responses in 50% of the cells. Figure 8B summa-
rizes the relationship between the duration of the depolar-
izing command and the exocytotic response. The average
responses tended to plateau within 50–100 ms with a
secondary acceleration becoming apparent for pulse du-
rations 200 ms.
The voltage dependence of exocytosis in -cells is
shown in Fig. 8C. Responses were small for depolariza-
tions to membrane potentials more negative than 10 mV.
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FIG. 6. Effects of Ca
2-channel antagonists on glucagon secretion. A: Glucagon secretion measured in the absence (open bars) and presence
(ﬁlled bars) of 10 mol/l isradipine. *P < 0.01 versus 1 mmol/l glucose alone, †P < 0.05 versus 1 mmol/l glucose and 10 mol/l isradipine. 100% 
10.5  0.6 pg/islet/h (n  9; 3 donors). B: Same as in A but effects of 200 nmol/l -agatoxin were tested. *P < 0.01 versus 1 mmol/l glucose alone,
100%  21.1  3.7 pg/islet/h (n  9; 3 donors).
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izations to 0 mV.
As shown in Fig. 8D, exocytosis elicited by a 500-ms
depolarization from 70 to 0 mV was inhibited by 97 	 3%
(P  0.05; n 
 4) by -agatoxin. Exocytosis was not
affected by stromatoxin, heteropodatoxin-2, and TTX
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FIG. 7. Electrical activity and [Ca
2]i oscillations. A: Membrane potential recording from an -cell exposed to 1 mmol/l glucose. Note prominent
after-hyperpolarizations after each action potential (arrows). B: Effect of tolbutamide on -cell membrane potential in two representative cells.
Note reduction of peak voltage. C: Spontaneous [Ca
2]i oscillations in an -cell within an intact islet exposed to 1 mmol/l glucose before and
during addition of 5 mol/l adrenaline. D:A si nC but testing the effects of -agatoxin (200 nmol/l), isradipine (10 mol/l), Bay K8644 (10 mol/l),
and K
 (70 mmol/l) at 1 mmol/l glucose. The inset shows the segment of the recording highlighted in gray on an expanded timebase. E: Histogram
summarizing the average amplitude of the [Ca
2]i oscillations under the indicated experimental conditions (13 cells in four islets obtained from
two donors; *P < 0.01, **P < 0.001 vs. 1 mmol/l glucose or as indicated by brackets). F:A si nD but -agatoxin was not applied. G: Histogram
summarizing results obtained as described in F from 14 cells in four islets from two donors (**P < 0.001 vs. 1 mmol/l glucose).
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4-aminopyridine. Thus, the strong inhibitory effect of
4-aminopyridine on glucagon secretion may result from
direct interference with -cell exocytosis.
DISCUSSION
We have conducted the ﬁrst electrophysiological charac-
terization of the ion channels involved in human -cell
action potential ﬁring and glucagon secretion. We demon-
strate that human -cells, like their rodent counterparts
(13), are electrically active at low glucose concentrations
and generate spontaneous oscillations in [Ca
2]i. The
spontaneous [Ca
2]i oscillations observed at 1 mmol/l
glucose were reduced (but not abolished) by the L-type
Ca
2-channel blocker isradipine, an effect that could be
antagonized by the L-type Ca
2-channel agonist BayK8644.
The isradipine-resistant [Ca
2]i oscillations are likely to
reﬂect Ca
2-inﬂux via P/Q-type and/or T-type Ca
2-chan-
nels. In agreement with this interpretation, the [Ca
2]i-
oscillations were completely suppressed when isradipine
was applied to islets exposed to the P/Q-type Ca
2-channel
blocker -agatoxin. Collectively, these ﬁndings make clear
that the [Ca
2]i oscillations depend on inﬂux of extracel-
lular Ca
2.
It is surprising that -agatoxin alone only had a minor
effect on [Ca
2]i although it strongly suppressed glucagon
secretion and P/Q-type channels account for 70% of the
whole-cell Ca
2-currents. This indicates that these chan-
nels activate very brieﬂy during the peak of the action
potentials and therefore mediate only a fraction of the
Ca
2-entry during electrical activity. These observations
suggest that P/Q-type Ca
2-channels are tightly linked to
the exocytosis of the glucagon granules. Indeed, the
capacitance measurements revealed that depolarization-
evoked exocytosis was completely dependent on Ca
2-
inﬂux through P/Q-type Ca
2-channels.
We addressed the potential roles of somatostatin and
insulin as paracrine regulators of glucagon secretion.
Blocking somatostatin-receptor subtype 2 (the subtype
expressed in human -cells; supplementary Fig. S1 and ref
[30]) does not interfere with the ability of glucose to
inhibit glucagon secretion. In accordance with previous in
vivo observations in human (31) and isolated mouse islets
(32), insulin inhibited glucagon secretion from human
islets exposed to 1 mmol/l glucose. Although it would be
tempting to interpret this ﬁnding in terms of insulin
mediating the inhibitory effect of glucose on glucagon
secretion, it should be noted that glucagon secretion is
inhibited over a range of glucose concentrations with
relatively small effects on insulin secretion. In fact, the
stronger stimulation of insulin secretion occurring at
glucose concentrations above 6 mmol/l coincides with
stimulation (not inhibition) of glucagon secretion. Unlike
what is seen in rat islets (33), Zn
2 stimulated glucagon
secretion from human islets. The reason for this difference
is unclear, but it is pertinent that several voltage-gated
channels expressed in human -cells are modulated by
Zn
2 (A-currents, T-type Ca
2-channels [34]). The stimu-
latory effects of insulin and Zn
2 may underlie the reduced
inhibition of glucagon secretion seen above 6 mmol/l
glucose (Fig. 1).
It has been proposed that glucose inhibits glucagon
secretion by inhibition of KATP-channels, leading to mem-
brane depolarization and voltage-dependent inactivation
of voltage-gated ion channels involved in action potential
ﬁring (14). We have so far not observed consistent effects
of glucose on membrane potential and conductance of
isolated human -cells. This may reﬂect technical difﬁcul-
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stable enough to assess glucose effects, which develop
over several minutes. However, tolbutamide promptly
depolarized the -cells by 10 mV and decreased the peak
voltage of the action potential, although it was without
detectable effect on the resting membrane conductance.
Thus, minute changes in KATP-channel activity have strong
effects on -cell electrical activity. Importantly, several of
the voltage-gated membrane currents in human -cells
exhibit voltage-dependent inactivation, and this may ac-
count for the observed reduction of the action potentials
peak voltage. Exocytosis in -cells shows a strong depen-
dence on voltage (Fig. 8C). A decrease in peak voltage of
the action potential can therefore be expected to exert a
strong inhibitory effect on glucagon secretion. A role of
membrane depolarization mediated by closure of KATP-
channels in the glucose-induced suppression of glucagon
secretion is suggested by our previous ﬁnding that micro-
molar concentrations of the KATP-channel activator dia-
zoxide antagonize the effect of the sugar (7).
The ion channel complements of human - and -cells
show great similarities, and the inactivation and activation
properties are very similar (20). Why then does membrane
depolarization produced by tolbutamide stimulate insulin
and somatostatin secretion (19,20) but inhibit glucagon
secretion (7)? Key electrophysiological characteristics of
human islet cells are summarized in supplementary Table
1, available in an online appendix. It can be seen that the
-cell differs from the other islet cells in having a low
resting membrane conductance. Perhaps as a result of
this, the interspike membrane potential of the -cell is
more depolarized than that of the - and 
-cells. Another
difference is that the Na
-current, which contributes to the
upstroke of the action potential, is smaller in the -cells
than in - and 
-cells. The more depolarized interspike
potential exacerbates this difference, and the Na
-current
that remains available for action potential ﬁring is only 1
pA/pF in -cells compared with 12 pA/pF in - and 
-cells.
In addition, -cells can be distinguished from -cells by
the presence of a prominent A-type K
-current. The func-
tional signiﬁcance of this current is underscored by the
observation that heteropodatoxin-2, like the KV2.1/2.2 an-
tagonist stromatoxin, is a strong inhibitor of glucagon
secretion. The transient hyperpolarization (“after-hyperpo-
larization,” Fig. 7A) after each action potential that results
from the activation of these channels may be particularly
important for reactivation of the Na
-channels in -cells.
Both types of K
-currents undergo partial voltage-depen-
dent inactivation at physiological membrane potentials,
and the A-current is almost completely inactivated at the
interspike potential attained in the presence of tolbut-
amide. It is possible that the -cells have a greater capacity
to repolarize the membrane voltage in the presence of
tolbutamide (and glucose) because the downstroke of the
action potential is due to opening of Ca
2-activated BK-
channels (20). These K
-channels may be less susceptible
to voltage-dependent inactivation, so that action potential
height is maintained also during sustained membrane
depolarization. More work is clearly needed to establish
precisely how glucose regulates glucagon secretion. The
ﬁndings reported here illustrate, however, that -cell elec-
trical activity depends on a complex balance between
depolarizing and repolarizing conductances and that any
process that perturbs this balance has dramatic effects on
glucagon secretion.
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